Pathogenic mechanisms in the initiation and progression of mammary phyllodes tumours

Pathology

Volumn 41, Issue 2, 2009, Pages 105-117

  Karim, Rooshdiya Z ^a,b,c   Scolyer, Richard A ^a,b,c   Tse, Gary M ^g   Tan, Puay Hoon ^h   Putti, Thomas C ⁱ   Lee, C Soon ^a,d,e,f,j  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b CANCER INSTITUTE NSW   (Australia)

^c University of Sydney   (Australia)

^d LIVERPOOL HOSPITAL   (Australia)

^e UNIVERSITY OF WESTERN SYDNEY   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^h SINGAPORE GENERAL HOSPITAL   (Singapore)

ⁱ NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^j SYDNEY SOUTH WEST AREA HEALTH SERVICE   (Australia)

more..

Author keywords

Angiogenesis; Breast; Cell cycle; Growth factor receptor; Hormone receptor; Pathogenesis; Phyllodes tumour; Wnt

Indexed keywords

CELL CYCLE PROTEIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; ENDOTHELIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; GLUCOCORTICOID RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MATRIX METALLOPROTEINASE; NITROGEN OXIDE; PLATELET DERIVED GROWTH FACTOR; PROGESTERONE RECEPTOR; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; TYROSINE KINASE RECEPTOR; VASCULOTROPIN;

ANGIOGENESIS; BREAST CANCER; CANCER GROWTH; CYSTOSARCOMA PHYLLOIDES; HISTOPATHOLOGY; HUMAN; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW;

EID: 61649107906     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020802579342     Document Type: Article

References (124)

1. Tavassoli FPD. Pathology and Genetics: Tumours of the Breast and Female Genital Tract, No. 4. Lyon, France: IARC, 2003.
2. Bernstein L, Deapen D, Ross RK. The descriptive epidemiology of malignant cystosarcoma phyllodes tumors of the breast. Cancer 1993; 71: 3020-4.
3. Cheng S-P, Chang Y-C, Liu T-P, Lee J-J, Tzen C-Y, Liu C-L. Phyllodes tumor of the breast: the challenge persists. World J Surg 2006; 30: 1414-21.
4. Parker SJ, Harries SA. Phyllodes tumours. Postgrad Med J 2001; 77: 428-35.
5. Matrisian LM, Cunha GR, Mohla S. Epithelial-stromal interactions and tumor progression: meeting summary and future directions. Cancer Res 2001; 61: 3844-6.
6. Parmar H, Cunha GR. Epithelial-stromal interactions in the mouse and human mammary gland in vivo. Endocr Relat Cancer 2004; 11: 437-58.
7. Fleming JM, Leibowitz BJ, Kerr DE, Cohick WS. IGF-I differentially regulates IGF-binding protein expression in primary mammary fibroblasts and epithelial cells. J Endocrinol 2005; 186: 165-78.
8. Wilson CL, Sims AH, Howell A, Miller CJ, Clarke RB. Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue. Endocr Relat Cancer 2006; 13: 617-28.
9. Kuijper A, Buerger H, Simon R, et al. Analysis of the progression of fibroepithelial tumours of the breast by PCR-based clonality assay. J Pathol 2002; 197: 575-81.
10. Dietrich CU, Pandis N, Rizou H, et al. Cytogenetic findings in phyllodes tumors of the breast: karyotypic complexity differentiates between malignant and benign tumors. Hum Pathol 1997; 28: 1379-82.
11. Wang ZC, Buraimoh A, Iglehart JD, Richardson AL. Genome-wide analysis for loss of heterozygosity in primary and recurrent phyllodes tumor and fibroadenoma of breast using single nucleotide polymorphism arrays. Breast Cancer Res Treat 2006; 97: 301-9.
12. Sawyer EJ, Hanby AM, Ellis P, et al. Molecular analysis of phyllodes tumors reveals distinct changes in the epithelial and stromal components. Am J Pathol 2000; 156: 1093-8.
13. Sawhney N, Garrahan N, Douglas-Jones AG, Williams ED. Epithelial-stromal interactions in tumors. A morphologic study of fibroepithelial tumors of the breast. Cancer 1992; 70: 2115-20.
14. Brosens JJ, Tullet J, Varshochi R, Lam EWF. Steroid receptor action. Best Pract Res Clin Obstet Gynaecol 2004; 18: 265-83.
15. Cheung KL. Endocrine therapy for breast cancer: an overview. Breast 2007; 16: 327-43.
16. Tse GMK, Lee CS, Kung FYL, et al. Hormonal receptors expression in epithelial cells of mammary phyllodes tumors correlates with pathologic grade of the tumor: a multicenter study of 143 cases. Am J Clin Pathol 2002; 118: 522-6.
17. Suo Z, Nesland JM. Phyllodes tumor of the breast: EGFR family expression and relation to clinicopathological features. Ultrastruct Pathol 2000; 24: 371-81.
18. Umekita Y, Yoshida H. Immunohistochemical study of hormone receptor and hormone-regulated protein expression in phyllodes tumour: comparison with fibroadenoma. Virchows Arch 1998; 433: 311-4.
19. Sapino A, Bosco M, Cassoni P, et al. Estrogen receptor-beta is expressed in stromal cells of fibroadenoma and phyllodes tumors of the breast. Mod Pathol 2006; 19: 599-606.
20. Shoker BS, Jarvis C, Clarke RB, et al. Abnormal regulation of the oestrogen receptor in benign breast lesions. J Clin Pathol 2000; 53: 778-83.
21. Lien HC, Lu YS, Cheng AL, et al. Differential expression of glucocorticoid receptor in human breast tissues and related neoplasms. J Pathol 2006; 209: 317-27.
22. Zandi R, Larsen AB, Andersen P, Stockhausen M-T, Poulsen HS. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal 2007; 19: 2013-23.
23. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366: 2-16.
24. Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 2004; 102: 37-46.
25. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 2002; 7 (Suppl 4): 31-9.
26. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002; 7 (Suppl 4): 2-8.
27. Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumors. Cancer Control 2007; 14: 295-304.
28. Moller P, Mechtersheimer G, Kaufmann M, et al. Expression of epidermal growth factor receptor in benign and malignant primary tumours of the breast. Virchows Arch A Pathol Anat Histopathol 1989; 414: 157-64.
29. Tse GM, Lui PC, Vong JS, et al. Increased epidermal growth factor receptor (EGFR) expression in malignant mammary phyllodes tumors. Breast Cancer Res Treat 2008 Apr 29: (Epub ahead of print).
30. Kersting C, Kuijper A, Schmidt H, et al. Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression. Lab Invest 2006; 86: 54-61.
31. Wang X, Jones TD, Zhang S, et al. Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate. Mod Pathol 2007; 20: 175-82.
32. Agelopoulos K, Kersting C, Korsching E, et al. Egfr amplification specific gene expression in phyllodes tumours of the breast. Cell Oncol 2007; 29: 443-51.
33. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001; 61 (Suppl 2): 1-13.
34. Menard S, Fortis S, Castiglioni F, Agresti R, Balsari A. HER2 as a prognostic factor in breast cancer. Oncology 2001; 61 (Suppl 2): 67-72.
35. Tan-Chiu E, Piccart M. Moving forward: Herceptin in the adjuvant setting. Oncology 2002; 63 (Suppl 1): 57-63.
36. Yonemori K, Hasegawa T, Shimizu C, et al. Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast. Pathol Res Pract 2006; 202: 705-12.
37. Shpitz B, Bomstein Y, Sternberg A, et al. Immunoreactivity of p53, Ki-67, and c-erbB-2 in phyllodes tumors of the breast in correlation with clinical and morphologic features. J Surg Oncol 2002; 79: 86-92.
38. Karim R, Tse G, Putti T, Scolyer R, Lee S. The significance of the Wnt pathway in the pathology of human cancers. Pathology 2004; 36: 120-8.
39. Akiyama T. Wnt/beta-catenin signaling. Cytokine Growth Factor Rev 2000; 11: 273-82.
40. Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14: 1837-51.
41. Seidensticker MJ, Behrens J. Biochemical interactions in the wnt pathway. Biochim Biophys Acta 2000; 1495: 168-82.
42. Yamaguchi TP. Heads or tails: Wnts and anterior-posterior patterning. Curr Biol 2001; 11: R713-24.
43. Sawyer EJ, Hanby AM, Rowan AJ, et al. The Wnt pathway, epithelial-stromal interactions, and malignant progression in phyllodes tumours. J Pathol 2002; 196: 437-44.
44. Sawyer EJ, Hanby AM, Poulsom R, et al. Beta-catenin abnormalities and associated insulin-like growth factor overexpression are important in phyllodes tumours and fibroadenomas of the breast. J Pathol 2003; 200: 627-32.
45. Sawyer EJ, Poulsom R, Hunt FT, et al. Malignant phyllodes tumours show stromal overexpression of c-myc and c-kit. J Pathol 2003; 200: 59-64.
46. Li W, Sanki A, Karim RZ, et al. The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology 2006; 38: 287-301.
47. Nurse P, Masui Y, Hartwell L. Understanding the cell cycle. Nat Med 1998; 4: 1103-6.
48. Michalides R. Cell cycle regulators: role in etiology, prognosis and treatment in cancer. Ann Oncol 2002; 13 (Suppl 4): 39.
49. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266: 1821-8.
50. Sparrow LE, Eldon MJ, English DR, Heenan PJ. p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry. Am J Dermatopathol 1998; 20: 255-61.
51. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994; 8: 15-21.
52. Ohnishi H, Kawamura M, Ida K, et al. Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood 1995; 86: 1269-75.
53. Giani C, Finocchiaro G. Mutation rate of the CDKN2 gene in malignant gliomas. Cancer Res 1994; 54: 6338-9.
54. Shapiro GI, Edwards CD, Kobzik L, et al. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res 1995; 55: 505-9.
55. Igaki H, Sasaki H, Tachimori Y, et al. Mutation frequency of the p16/ CDKN2 gene in primary cancers in the upper digestive tract. Cancer Res 1995; 55: 3421-3.
56. Yoshida S, Todoroki T, Ichikawa Y, et al. Mutations of p16Ink4/ CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. Cancer Res 1995; 55: 2756-60.
57. Merlo A, Herman JG, Mao L, et al. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. [See comment]. Nat Med 1995; 1: 686-92.
58. Jones AM, Mitter R, Springall R, et al. A comprehensive genetic profile of phyllodes tumours of the breast detects important mutations, intra-tumoral genetic heterogeneity and new genetic changes on recurrence. J Pathol 2008; 214: 533-44.
59. Kuijper A, de Vos RAI, Lagendijk JH, van der Wall E, van Diest PJ. Progressive deregulation of the cell cycle with higher tumor grade in the stroma of breast phyllodes tumors. Am J Clin Pathol 2005; 123: 690-8.
60. Esposito NN, Mohan D, Brufsky A, Lin Y, Kapali M, Dabbs DJ. Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases. Arch Pathol Lab Med 2006; 130: 1516-21.
61. Singh M, Parnes MB, Spoelstra N, Bleile MJ, Robinson WA. p16 expression in sentinel nodes with metastatic breast carcinoma: evaluation of its role in developing triaging strategies for axillary node dissection and a marker of poor prognosis. Hum Pathol 2004; 35: 1524-30.
62. Lee CT, Capodieci P, Osman I, et al. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin Cancer Res 1999; 5: 977-83.
63. Pei XH, Xiong Y. Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues. Oncogene 2005; 24: 2787-95.
64. Lae M, Vincent-Salomon A, Savignoni A, et al. Phyllodes tumors of the breast segregate in two groups according to genetic criteria. Mod Pathol 2007; 20: 435-44.
65. Korabiowska M, Ruschenburg I, Betke H, et al. Downregulation of the retinoblastoma gene expression in the progression of malignant melanoma. Pathobiology 2001; 69: 274-80.
66. Brantley MA Jr, Harbour JW. Deregulation of the Rb and p53 pathways in uveal melanoma. Am J Pathol 2000; 157: 1795-801.
67. Schulze A, Zerfass K, Spitkovsky D, et al. Cell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F site. Proc Natl Acad Sci USA 1995; 92: 11264-8.
68. Zhang H, Xiong Y, Beach D. Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol Biol Cell 1993; 4: 897-906.
69. Dobashi Y, Shoji M, Jiang SX, Kobayashi M, Kawakubo Y, Kameya T. Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. Am J Pathol 1998; 153: 963-72.
70. Bukholm IR, Bukholm G, Nesland JM. Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas. Int J Cancer 2001; 93: 283-7.
71. Lammie GA, Fantl V, Smith R, et al. D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene 1991; 6: 439-44.
72. Barbieri F, Cagnoli M, Ragni N, et al. Increased cyclin D1 expression is associated with features of malignancy and disease recurrence in ovarian tumors. Clin Cancer Res 1999; 5: 1837-42.
73. Kim SH, Lewis JJ, Brennan MF, Woodruff JM, Dudas M, Cordon-Cardo C. Overexpression of cyclin D1 is associated with poor prognosis in extremity soft-tissue sarcomas. Clin Cancer Res 1998; 4: 2377-82.
74. Naitoh H, Shibata J, Kawaguchi A, Kodama M, Hattori T. Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer. Am J Pathol 1995; 146: 1161-9.
75. Kornmann M, Ishiwata T, Itakura J, Tangvoranuntakul P, Beger HG, Korc M. Increased cyclin D1 in human pancreatic cancer is associated with decreased postoperative survival. Oncology 1998; 55: 363-9.
76. Li JY, Gaillard F, Moreau A, et al. Detection of translocation t(11; 14)(q13; q32) in mantle cell lymphoma by fluorescence in situ hybridization. Am J Pathol 1999; 154: 1449-52.
77. de Boer CJ, Schuuring E, Dreef E, et al. Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma. Blood 1995; 86: 2715-23.
78. Avet-Loiseau H, Li JY, Facon T, et al. High incidence of translocations t(11; 14)(q13; q32) and t(4; 14)(p16; q32) in patients with plasma cell malignancies. Cancer Res 1998; 58: 5640-5.
79. Bhatt KV, Hu R, Spofford LS, Aplin AE. Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells. Oncogene 2007; 26: 1056-66.
80. Sauter ER, Yeo UC, von Stemm A, et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res 2002; 62: 3200-6.
81. Bhatt KV, Spofford LS, Aram G, McMullen M, Pumiglia K, Aplin AE. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene 2005; 24: 3459-71.
82. Kleer CG, Giordano TJ, Braun T, Oberman HA. Pathologic, immunohistochemical, and molecular features of benign and malignant phyllodes tumors of the breast. Mod Pathol 2001; 14: 185-90.
83. Tan PH, Jayabaskar T, Yip G, et al. p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study. Mod Pathol 2005; 18: 1527-34.
84. Millar EK, Beretov J, Marr P, et al. Malignant phyllodes tumours of the breast display increased stromal p53 protein expression. Histopathology 1999; 34: 491-6.
85. Tse GMK, Putti TC, Kung FYL, et al. Increased p53 protein expression in malignant mammary phyllodes tumors. [Erratum appears in Mod Pathol 2002; 15: 1010.] Mod Pathol 2002; 15: 734-40.
86. Tse GMK, Lui PCW, Scolyer RA, et al. Tumour angiogenesis and p53 protein expression in mammary phyllodes tumors. Mod Pathol 2003; 16: 1007-13.
87. Dacic S, Kounelis S, Kouri E, Jones MW. Immunohistochemical profile of cystosarcoma phyllodes of the breast: a study of 23 cases. Breast J 2002; 8: 376-81.
88. Erhan Y, Zekioglu O, Ersoy O, et al. p53 and Ki-67 expression as prognostic factors in cystosarcoma phyllodes. Breast J 2002; 8: 38-44.
89. Tomita T, Ren Y, Davis M, Tawfik O. Phyllodes tumor of borderline malignancy: a 7-year follow-up. Breast J 2003; 9: 333-4.
90. Gatalica Z, Finkelstein S, Lucio E, et al. p53 protein expression and gene mutation in phyllodes tumors of the breast. Pathol Res Pract 2001; 197: 183-7.
91. Niezabitowski A, Lackowska B, Rys J, et al. Prognostic evaluation of proliferative activity and DNA content in the phyllodes tumor of the breast: immunohistochemical and flow cytometric study of 118 cases. Breast Cancer Res Treat 2001; 65: 77-85.
92. Koo CY, Bay BH, Lui PCW, Tse GMK, Tan PH, Yip GWC. Immunohistochemical expression of heparan sulfate correlates with stromal cell proliferation in breast phyllodes tumors. Mod Pathol 2006; 19: 1344-50.
93. Tse GMK, Lui PCW, Lee CS, et al. Stromal expression of vascular endothelial growth factor correlates with tumor grade and microvessel density in mammary phyllodes tumors: a multicenter study of 185 cases. Hum Pathol 2004; 35: 1053-7.
94. Kuijper A, van der Groep P, van der Wall E, van Diest PJ. Expression of hypoxia-inducible factor 1 alpha and its downstream targets in fibroepithelial tumors of the breast. Breast Cancer Res 2005; 7: R808-18.
95. Feakins RM, Wells CA, Young KA, Sheaff MT. Platelet-derived growth factor expression in phyllodes tumors and fibroadenomas of the breast. Hum Pathol 2000; 31: 1214-22.
96. Tse GM, Chaiwun B, Lau K-M, et al. Endothelin-1 expression correlates with atypical histological features in mammary phyllodes tumours. J Clin Pathol 2007; 60: 1051-6.
97. Tse GMK, Wong FC, Tsang AKH, et al. Stromal nitric oxide synthase (NOS) expression correlates with the grade of mammary phyllodes tumour. J Clin Pathol 2005; 58: 600-4.
98. Forrester K, Ambs S, Lupold SE, et al. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Natl Acad Sci USA 1996; 93: 2442-7.
99. Gallo O, Schiavone N, Papucci L, et al. Down-regulation of nitric oxide synthase-2 and cyclooxygenase-2 pathways by p53 in squamous cell carcinoma. Am J Pathol 2003; 163: 723-32.
100. Pukkila MJ, Kellokoski JK, Virtaniemi JA, et al. Inducible nitric oxide synthase expression in pharyngeal squamous cell carcinoma: relation to p53 expression, clinicopathological data, and survival. Laryngoscope 2002; 112: 1084-8.
101. Tse GM, Ma TK, Chan KF, et al. Increased microvessel density in malignant and borderline mammary phyllodes tumours. Histopathology 2001; 38: 567-70.
102. Tse GMK, Putti TC, Lui PCW, et al. Increased c-kit (CD117) expression in malignant mammary phyllodes tumors. Mod Pathol 2004; 17: 827-31.
103. Carvalho S, e Silva AO, Milanezi F, et al. c-KIT and PDGFRA in breast phyllodes tumours: overexpression without mutations? J Clin Pathol 2004; 57: 1075-9.
104. Chen CM, Chen CJ, Chang CL, Shyu JS, Hsieh HF, Harn HJ. CD34, CD117, and actin expression in phyllodes tumor of the breast. J Surg Res 2000; 94: 84-91.
105. Tse GMK, Tsang AKH, Putti TC, et al. Stromal CD10 expression in mammary fibroadenomas and phyllodes tumours. J Clin Pathol 2005; 58: 185-9.
106. Tsai W-C, Jin J-S, Yu J-C, Sheu L-F. CD10, actin, and vimentin expression in breast phyllodes tumors correlates with tumor grades of the WHO grading system. Int J Surg Pathol 2006; 14: 127-31.
107. Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG. Stromal CD10 expression in invasive breast carcinoma correlates with poor prognoaia, estrogen receptor negativity and high grade. Mod Pathol 2007; 20: 84-9.
108. Zamecnik M, Kinkor Z, Chlumska A. CD10+ stromal cells in fibroadenomas and phyllodes tumors of the breast. Virchows Arch 2006; 448: 871-2.
109. Hughes TA, Brady HJM. Cross-talk between pRb/E2F and Wnt/ beta-catenin pathways: E2F1 induces axin2 leading to repression of Wnt signalling and to increased cell death. Exp Cell Res 2005; 303: 32-46.
110. Ruiz S, Segrelles C, Santos M, Lara MF, Paramio JM. Functional link between retinoblastoma family of proteins and the Wnt signaling pathway in mouse epidermis. Dev Dyn 2004; 230: 410-8.
111. Tan X, Apte U, Micsenyi A, et al. Epidermal growth factor receptor: a novel target of the Wnt/beta-catenin pathway in liver. Gastroenterology 2005; 129: 285-302.
112. Civenni G, Holbro T, Hynes NE. Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells. [Erratum appears in EMBO Rep. 2003 Mar; 4: 326.] EMBO Rep 2003; 4: 166-71.
113. Kim S-E, Choi K-Y. EGF receptor is involved in WNT3a-mediated proliferation and motility of NIH3T3 cells via ERK pathway activation. Cell Signal 2007; 19: 1554-64.
114. Faivre EJ, Lange CA. Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. Mol Cell Biol 2007; 27: 466-80.
115. Mulholland DJ, Dedhar S, Coetzee GA, Nelson CC. Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? Endocr Rev 2005; 26: 898-915.
116. Yang F, Li X, Sharma M, et al. Linking beta-catenin to androgen-signaling pathway. J Biol Chem 2002; 277: 11336-44.
117. Takayama S, Rogatsky I, Schwarcz LE, Darimont BD. The glucocorticoid receptor represses cyclin D1 by targeting the Tcf-beta-catenin complex. J Biol Chem 2006; 281: 17856-63.
118. Kouzmenko AP, Takeyama K-I, Ito S, et al. Wnt/beta-catenin and estrogen signaling converge in vivo. J Biol Chem 2004; 279: 40255-8.
119. Das SK, Tan J, Raja S, Halder J, Paria BC, Dey SK. Estrogen targets genes involved in protein processing, calcium homeostasis, and Wnt signaling in the mouse uterus independent of estrogen receptor-alpha and -beta. J Biol Chem 2000; 275: 28834-42.
120. Robinson GW, Hennighausen L, Johnson PF. Side-branching in the mammary gland: the progesterone-Wnt connection. Genes Dev 2000; 14: 889-94.
121. Tulac S, Overgaard MT, Hamilton AE, Jumbe NL, Suchanek E, Giudice LC. Dickkopf-1, an inhibitor of Wnt signaling, is regulated by progesterone in human endometrial stromal cells. J Clin Endocrinol Metab 2006; 91: 1453-61.
122. Rider V, Isuzugawa K, Twarog M, et al. Progesterone initiates Wnt-beta-catenin signaling but estradiol is required for nuclear activation and synchronous proliferation of rat uterine stromal cells. J Endocrinol 2006; 191: 537-48.
123. Forget MA, Turcotte S, Beauseigle D, et al. The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types. Br J Cancer 2007; 96: 646-53.
124. Rao BR, Meyer JS, Fry CG. Most cystosarcoma phyllodes and fibroadenomas have progesterone receptor but lack estrogen receptor: stromal localization of progesterone receptor. Cancer 1981; 47: 2016-21.